CLINICAL ROLE -
First-in-Class Immunotoxin Shows Durable Response in Hairy Cell Leukemia
Moxetumomab pasudotox is a nonchemotherapeutic drug that could become the standard of care for patients with relapsed/refractory hairy cell leukemia.
Read More
Keytruda Improves Progression-Free Survival in Advanced Hepatocellular Carcinoma
Prior treatment with sorafenib followed by pembrolizumab (Keytruda) shows promising progression-free survival and overall survival in patients with advanced hepatocellular carcinoma.
Nivolumab Shows Promise Treating Gastrointestinal Tumors
Nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy) induced responses in patients with heavily pretreated gastrointestinal stromal tumors.
Cyramza Added to Chemo Regimen Not Found to Improve Gastric Cancer Survival
The addition of ramucirumab did not improve overall survival in patients with HER2-negative gastric cancer.